Woun
d healing is a complex process, coor
dinate
d by various biological factors. In immunocompromise
d states woun
d healing can be interrupte
d as a result of
decrease
d numbers of immune cells, impairing the pro
duction of effector molecules such as nitric oxi
de (NO). Therefore, topical NO-releasing platforms, such as
diethylenetriamine (DETA NONOate), have been investigate
d to enhance woun
d healing. Recently, we
demonstrate
d a nanoparticle platform that releases NO (NO-NPs) in a sustaine
d manner, accelerating woun
d healing in both uninfecte
d an
d infecte
d murine woun
d mo
dels. Here, NO-NPs were investigate
d an
d compare
d to DETA NONOate in an immunocompromise
d woun
d mo
del using non-obese,
diabetic, severe combine
d immuno
deficiency mice. NO-NP treatment accelerate
d woun
d closure as compare
d to controls an
d DETA NONOate treatment. In a
ddition, histological assessment reveale
d that woun
ds treate
d with NO-NPs ha
d less inflammation, more collagen
deposition, an
d more bloo
d vessel formation as compare
d to other groups, consistent with our previous
data in immunocompetent animals. These
data suggest that NO-NPs may serve as a novel woun
d-healing therapy in the setting of immunocompromise
d states associate
d with impaire
d woun
d healing.
From the Clinical Editor
Wound healing in an immunocompromised host is often incomplete and is a source of major concern in such conditions. This work demonstrates in a murine model that in these settings NO releasing nanoparticles significantly enhance wound healing.